Michael Danso

4.5k total citations · 2 hit papers
60 papers, 2.6k citations indexed

About

Michael Danso is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Michael Danso has authored 60 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 29 papers in Pulmonary and Respiratory Medicine and 16 papers in Genetics. Recurrent topics in Michael Danso's work include Advanced Breast Cancer Therapies (27 papers), Cancer Treatment and Pharmacology (26 papers) and HER2/EGFR in Cancer Research (23 papers). Michael Danso is often cited by papers focused on Advanced Breast Cancer Therapies (27 papers), Cancer Treatment and Pharmacology (26 papers) and HER2/EGFR in Cancer Research (23 papers). Michael Danso collaborates with scholars based in United States, Italy and Japan. Michael Danso's co-authors include Clifford A. Hudis, Ethan Basch, Ashley S. Doane, William L. Gerald, Priti Lal, Karin Jordan, Mark G. Kris, Kari Bohlke, Gary H. Lyman and Paul J. Hesketh and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Michael Danso

54 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

2017 397 citations Ethan Basch, Michael Danso et al. Journal of Clinical Oncology profile →
Antiemetics: ASCO Guideline Update

2020 224 citations Ethan Basch, Michael Danso et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Danso United States	22	1.6k	725	672	618	584	60	2.6k
Kelly Pendergrass United States	19	1.1k 0.7×	808 1.1×	355 0.5×	369 0.6×	499 0.9×	31	2.3k
Susana M. Campos United States	28	1.6k 1.1×	449 0.6×	346 0.5×	859 1.4×	319 0.5×	101	3.3k
Gamini S. Soori United States	23	1.6k 1.1×	642 0.9×	387 0.6×	428 0.7×	332 0.6×	70	2.6k
Katsumasa Kuroi Japan	32	2.2k 1.4×	521 0.7×	1.3k 1.9×	869 1.4×	507 0.9×	143	3.8k
David Chu United States	27	1.1k 0.7×	674 0.9×	428 0.6×	1.1k 1.7×	319 0.5×	56	2.8k
Danika L. Lew United States	27	1.8k 1.1×	697 1.0×	1.1k 1.6×	408 0.7×	256 0.4×	72	2.8k
Rudolf Maibach Switzerland	33	1.6k 1.0×	864 1.2×	656 1.0×	697 1.1×	1.2k 2.1×	73	3.7k
Larissa A. Korde United States	27	1.7k 1.1×	767 1.1×	1.0k 1.6×	764 1.2×	373 0.6×	81	3.7k
Frans Erdkamp Netherlands	26	2.7k 1.8×	1.3k 1.8×	562 0.8×	572 0.9×	377 0.6×	82	3.7k
Michel Marty France	23	1.8k 1.2×	487 0.7×	743 1.1×	542 0.9×	570 1.0×	47	3.0k

Countries citing papers authored by Michael Danso

Since Specialization

Citations

This map shows the geographic impact of Michael Danso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Danso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Danso more than expected).

Fields of papers citing papers by Michael Danso

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Danso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Danso. The network helps show where Michael Danso may publish in the future.

Co-authorship network of co-authors of Michael Danso

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Danso. A scholar is included among the top collaborators of Michael Danso based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Danso. Michael Danso is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tolaney, Sara M., Zefei Jiang, Qingyuan Zhang, et al.. (2025). Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine. 394(6). 551–562. 2 indexed citations

Patel, Manish R., Rachel M. Layman, Michael Danso, et al.. (2024). Preliminary results from a phase 1 study of AC699, an orally bioavailable chimeric estrogen receptor degrader, in patients with advanced or metastatic breast cancer.. Journal of Clinical Oncology. 42(16_suppl). 3074–3074. 4 indexed citations

Al‐Sukhun, Sana, Sarah Temin, Carlos H. Barrios, et al.. (2024). Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource–Stratified Guideline. JCO Global Oncology. 10(10). e2300285–e2300285. 25 indexed citations

Njie, Ramou, Lamin Jaiteh, Ousman Nyan, et al.. (2024). Clinical Characteristics and Prognostic Factors of COVID‐19 Patients Admitted to the National Treatment Center in The Gambia. Advances in Public Health. 2024(1).

Telli, Melinda L., Jennifer K. Litton, J. Thaddeus Beck, et al.. (2024). Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status. Breast Cancer. 31(5). 886–897. 8 indexed citations

Campone, Mario, X. Cynthia, Michelino De Laurentiis, et al.. (2024). Abstract PO1-19-12: VERITAC-2: a phase 3 study of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer. Cancer Research. 84(9_Supplement). PO1–19. 1 indexed citations

Hamilton, E.P., Rachel M. Layman, Michael Danso, et al.. (2024). 637P AC699, a novel chimeric estrogen receptor degrader, in a phase I study in breast cancer. Annals of Oncology. 35. S505–S506.

Hamilton, Erika, X. Cynthia, Michelino De Laurentiis, et al.. (2023). 257TiP VERITAC-2: A global, randomized phase III study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer. ESMO Open. 8(1). 101445–101445. 6 indexed citations

Force, Jeremy, Joyce O’Shaughnessy, Sara A. Hurvitz, et al.. (2023). Neoadjuvant single-dose trilaciclib prior to combination chemotherapy in patients with early triple-negative breast cancer: Safety, efficacy, and immune correlate data from a phase 2 study.. Journal of Clinical Oncology. 41(16_suppl). 603–603. 1 indexed citations

10.

Seneviratne, Lasika, Kathleen Harnden, Sibel Blau, et al.. (2023). 201P Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Preliminary phase II results. ESMO Open. 8(1). 101390–101390. 5 indexed citations

11.

Tan, Antoinette R., Gail S. Wright, Anu Thummala, et al.. (2021). Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study. Clinical Cancer Research. 28(4). 629–636. 28 indexed citations

12.

Kalra, Maitri, Yan Tong, David Jones, et al.. (2021). Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer. npj Breast Cancer. 7(1). 29–29. 20 indexed citations

13.

Tan, Antoinette R., Gail S. Wright, Anu Thummala, et al.. (2019). Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial. The Lancet Oncology. 20(11). 1587–1601. 86 indexed citations

14.

Bardia, Aditya, Ayca Gucalp, Nashat Gabrail, et al.. (2018). Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer. Breast Cancer Research and Treatment. 171(1). 111–120. 35 indexed citations

15.

Danso, Michael, et al.. (2017). The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice. Quality of Life Research. 26(10). 2763–2772. 57 indexed citations

16.

Yardley, Denise A., James A. Reeves, Elizabeth Claire Dees, et al.. (2016). Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study. Clinical Breast Cancer. 16(6). 471–479.e1. 29 indexed citations

17.

Partridge, Ann H., R. Bryan Rumble, Lisa A. Carey, et al.. (2014). Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. 32(29). 3307–3329. 194 indexed citations

18.

Holmes, Frankie A., Virginia Espina, Lance A. Liotta, et al.. (2013). Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling. BMC Research Notes. 6(1). 507–507. 50 indexed citations

19.

Doane, Ashley S., et al.. (2006). An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 25(28). 3994–4008. 441 indexed citations

20.

Doane, Ashley S., Michael Danso, Priti Lal, et al.. (2006). Distinct PIK3CA mutation profiles in estrogen receptor (ER) negative breast cancer (BC) subsets. Journal of Clinical Oncology. 24(18_suppl). 540–540. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact